Skip to main content
. Author manuscript; available in PMC: 2011 Jul 28.
Published in final edited form as: Clin Pharmacokinet. 2008;47(6):399–415. doi: 10.2165/00003088-200847060-00004

Table I.

Descriptive statistics of the recombinant human erythropoietin individual maximum a posteriori Bayesian estimates of pharmacokinetic parameters from the population modela

Parameter Prior mean (% CV) Posterior mean (% CV) Range
Baseline serum erythropoietin (IU/L)b 13.9 (30) 11.4 (34) 6.2–26.6
CLI (Lh) 0.358 (33) 0.325 (15) 0.226–0.468
Vmax (IU/h) 211 (29) 239 (44) 83–634
V2(L) 3.89 (31) 4.17 (25) 1.81–7.10
F0 (%) 62 (35) 47 (42) 15–100
fr (%) 60 (45) 78 (46) 51–93
ka(/h) 0.034 (36) 0.039 (47) 0.016–0.155
D1 (h) 0.725 (125) 1.678 (102) 0.128–12.718
tlag2 (h) 2.72 (53) 2.75 (31) 1.00–5.47
a

Km was fixed at 394 IU/L, Q was fixed at 0.044 L/h, V3 was fixed at 1.64 L, D2 was fixed at 37.8 h, Emax(F) was fixed at 64.9% and ED50(F) was fixed at 63.2 kIU.

b

Circadian rhythm was fixed to values previously reported by Olsson-Gisleskog et al.[18]

CLI = linear clearance; CV = coefficient of variation; D1 = estimated duration of faster absorption phase; D2 = estimated duration of slower absorption phase; ED50(F) = dose giving 50% of increase in absolute bioavailability; Emax(F) = maximum increase in bioavailability with dose; F0 = minimum absolute bioavailability; fr = bioavailability fraction; ka = first-order absorption rate constant; Km = Michaelis-Menten constant; Q = intercompartmental clearance; tlag2 = lag time for the slower absorption phase; V2 = volume of distribution of the central compartment; V3 = volume of distribution of the peripheral compartment; Vmax = maximum elimination rate of the saturable pathway.